|
Alx Oncology Holdings Inc (NASDAQ: ALXO) |
|
Alx Oncology Holdings Inc
ALXO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Alx Oncology Holdings Inc's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Alx Oncology Holdings Inc net loss decreased from $-51 millions, to $-31 millions in III. Quarter 2024,
• More on ALXO's Growth
|
|
Alx Oncology Holdings Inc realized a net loss in trailing twelve months.
Alx Oncology Holdings Inc realized cash reduction of $ -0.07 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on ALXO's Valuation
|
|
|
|
|
Alx Oncology Holdings Inc realized net loss in trailing twelve months.
Alx Oncology Holdings Inc realized cash outflow of $ -0.07per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
Alx Oncology Holdings Inc Price to Book Ratio is at 0.42 lower than Industry Avg. of 89.07. and higher than S&P 500 Avg. of 0.01
• More on ALXO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com